Scott L, da Silva P, Boehme CC, Stevens W, Gilpin CM. Diagnosis of opportunistic infections: HIV co-infections—tuberculosis. Curr Opin HIV AIDS 2017; 12: 129–138.
Awuh JA, Flo TH. Molecular basis of mycobacterial survival in macrophages. Cell Mol Life Sci 2017; 74: 1625–1648.
Jasmer RM, Nahid P, Hopewell PC. Latent tuberculosis infection. N Engl J Med 2002; 347: 1860–1866.
Fan L, Shen H, Huang H, Yang R, Yao L. Impairment of Wnt/β-catenin signaling in blood cells of patients with severe cavitary pulmonary tuberculosis. PLoS One 2017; 12: e0172549.
Garib FY, Rizopulu AP. T regulatory cells as part of strategy of immune evasion by pathogens. Biochemistry (Moscow) 2015; 80: 957–971.
Stenger SNK, Modlin RL. Down-regulation of CD1 on antigen-presenting cells by infection with Mycobacterium tuberculosis. J Immunol 1998; 161: 3582–3588.
Sutton CE, Lalor SJ, Brereton CF, Sweeney CM, Lavelle EC, Mills KHG. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009; 31: 331–341.
Song X, He X, Li X, Qian Y. The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity. Cell Mol Immunol 2016; 13: 418–431.
Papotto PH, Ribot JC, Silva-Santos B. IL-17+ γδ T cells as kick-starters of inflammation. Nat Immunol 2017; 18: 604–611.
Umemura M, Yahagi A, Hamada S, Begum MD, Watanabe H, Kawakami K et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol 2007; 178: 3786–3796.
Tateosian NL, Pellegrini JM, Amiano NO, Rolandelli A, Casco N, Palmero DJ et al. IL17A augments autophagy in Mycobacterium tuberculosis-infected monocytes from patients with active tuberculosis in association with the severity of the disease. Autophagy 2017; 13: 1191–1204.
Khan N, Vidyarthi A, Amir M, Mushtaq K, Agrewala JN. T-cell exhaustion in tuberculosis: pitfalls and prospects. Crit Rev Microbiol 2017; 43: 133–141.
Rai PK, Chodisetti SB, Nadeem S, Maurya SK, Gowthaman U, Zeng W et al. A novel therapeutic strategy of lipidated promiscuous peptide against Mycobacterium tuberculosis by eliciting Th1 and Th17 immunity of host. Sci Rep 2016; 6: 23917.
Periasamy S, Dhiman R, Barnes PF, Paidipally P, Tvinnereim A, Bandaru A, VL et al. Programmed death 1 and cytokine inducible SH2-containing protein dependent expansion of regulatory T cells upon stimulation with Mycobacterium tuberculosis. J Infect Dis 2011; 203: 1256–1263.
Shen L, Shi H, Gao Y, Liu Q, Liu Y, Wu J et al. The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis. Tuberculosis (Edinb) 2016; 101: 146–150.
Bandaru A, Devalraju KP, Paidipally P, Dhiman R, Venkatasubramanian S, Barnes PF et al. Phosphorylated STAT3 and PD-1 regulate IL-17 production and IL-23 receptor expression in Mycobacterium tuberculosis infection. Eur J Immunol 2014; 44: 2013–2024.
Segueni N, Tritto E, Bourigault M-L, Rose S, Erard F, Bert ML et al. Controlled Mycobacterium tuberculosis infection in mice under treatment with anti-IL-17A or IL-17F antibodies, in contrast to TNFα neutralization. Sci Rep 2016; 6: 36923.
Milano M, Moraes MO, Rodenbusch R, Carvalho CX, Delcroix M, Mousquer G et al. Single nucleotide polymorphisms in IL17A and IL6 are associated with decreased risk for pulmonary tuberculosis in Southern Brazilian Population. PLoS One 2016; 11: e0147814.
Yoshida YO, Umemura M, Yahagi A, O’Brien RL, Ikuta K, Kishihara K et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 2010; 184: 4414–4422.
Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007; 8: 369–377.
Lombard R, Doz E, Carreras F, Epardaud M, Vern YL, Buzoni-Gatel D et al. IL-17RA in non-hematopoietic cells controls CXCL-1 and 5 critical to recruit neutrophils to the lung of mycobacteria-infected mice during the adaptive immune response. PLoS One 2016; 11: e0149455.
Danda D, Goel R, Danda S, Mohan H, Joseph G, Kabeerdoss J et al. Interleukin-17F and interleukin-6 gene polymorphisms in Asian Indian patients with Takayasu arteritis. Hum Immunol 2017; S0198-8859: 30070–30078.
Hongbo Shen YW, Chen CY, Frencher J, Huang D, Yang E, Ryan-Payseur B et al. Th17-related cytokines contribute to recall-like expansion/effector function of HMBPP-specific Vγ2Vδ2 T cells after M. tuberculosis infection or vaccination. Eur J Immunol 2015; 45: 442–451.
Venkatasubramanian S, Cheekatla S, Paidipally P, Tripathi D, Welch E, Tvinnereim AR et al. IL-21-dependent expansion of memory-like NK cells enhances protective immune responses against Mycobacterium tuberculosis. Mucosal Immunol 2016; 10: 1031–1042.
Wu C, Li Z, Fu X, Yu S, Lao S, Yang B. Antigen-specific human NKT cells from tuberculosis patients produce IL-21 to help B cells for the production of immunoglobulins. Oncotarget 2015; 6: 28633–28645.
Li L, Jiang Y, Lao S, Yang B, Yu S, Zhang Y et al. Mycobacterium tuberculosis-specific IL-21+IFN-γ+CD4+ T cells are regulated by IL-12. PLoS One 2016; 11: e0147356.
Booty MG, Barreira-Silva P, Carpenter SM, Nunes-Alves C, Jacques MK, Stowell BL et al. IL-21 signaling is essential for optimal host resistance against Mycobacterium tuberculosis infection. Sci Rep 2016; 6: 36720.
Plessis WJD, Kleynhans L, Plessis ND, Stanley K, Malherbe ST, Maasdorp E et al. The Functional response of B cells to antigenic stimulation: a preliminary report of latent tuberculosis. PLoS One 2016; 11: e0152710.
Bryant VL, Ma CS, Avery DT, Li Y, Good KL, Corcoran LM et al. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5+ T follicular helper cells. J Immunol 2007; 179: 8180–8190.
Kumar NP, Sridhar R, Hanna LE, Banurekha VV, Nutman TB, Babu S. Decreased frequencies of circulating CD4+ T follicular helper cells associated with diminished plasma IL-21 in active pulmonary tuberculosis. PLoS One 2014; 9: e111098.
Yao S, Huang D, Chen CY, Halliday L, Zeng G, Wang RC et al. Differentiation, distribution and gammadelta T cell-driven regulation of IL-22-producing T cells in tuberculosis. PLoS Pathog 2010; 6: e1000789.
Zhang M, Zeng G, Yang Q, Zhang J, Zhu X, Chen Q et al. Anti-tuberculosis treatment enhances the production of IL-22 through reducing the frequencies of regulatory B cell. Tuberculosis (Edinb) 2014; 94: 238–244.
Lee M-R, Tsai C-J, Wang W-J, Chuang T-Y, Yang C-M, Chang L-Y et al. Plasma biomarkers can predict treatment response in tuberculosis patients, a prospective observational study. Medicine (Baltimore) 2015; 94: e1628.
Cowan J, Pandey S, Filion LG, Angel JB, Kumar A, Cameron DW. Comparison of interferon-γ-, interleukin (IL)-17- and IL-22-expressing CD4 T cells, IL-22-expressing granulocytes and proinflammatory cytokines during latent and active tuberculosis infection. Clin Exp Immunol 2012; 167: 317–329.
Scriba TJ, Kalsdorf B, Abrahams DA, Isaacs F, Hofmeister J, Black G et al. Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 2008; 180: 1962–1970.
Guillon A, Jouan Y, Brea D, Gueugnon F, Dalloneau E, Baranek T et al. Neutrophil proteases alter the interleukin-22-receptor-dependent lung antimicrobial defence. Eur Respir J 2015; 46: 771–782.
Yao S, Huang D, Chen CY, Halliday L, Wang RC, Chen ZW. CD4+ T cells are required to contain early extrathoracic TB dissemination and sustain multi-effector functions of CD8+ T and CD3− lymphocytes. J Immunol 2014; 192: 2120–2132.
Dhiman R, Indramohan M, Barnes PF, Nayak RC, Paidipally P, Rao LVM et al. IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J Immunol 2009; 183: 6639–6645.
Søndergaard JN, Laursen JM, Rosholm LB, Brix S. Mycobacterium tuberculosis promotes Th17 expansion via regulation of human dendritic cells toward a high CD14 and low IL-12p70 phenotype that reprograms upon exogenous IFN-γ. Int Immunol 2014; 26: 705–716.
Zeng G, Chen CY, Huang D, Yao S, Wang RC, Chen ZW. Membrane-bound IL-22 after de novo production in tuberculosis and anti-Mycobacterium tuberculosis effector function of IL-22+ CD4+ T cells. J Immunol 2011; 187: 190–199.
Qiu Y, Huang Y, Qiao D, Zeng G, Cai J. Depletion of IL-22 during culture enhanced antigen-driven IFN-γ production by CD4+T cells from patients with active TB. Immunol Lett 2013; 150: 48–53.
Wilson MS, Feng CG, Barber DL, Yarovinsky F, Cheever AW, Sher A et al. Redundant and pathogenic roles for IL-22 in mycobacterial, protozoan, and helminth infections. J Immunol 2010; 184: 4378–4390.
Liyou Qiu DH, Chen CY, Wang R, Shen L, Shen Y, Hunt R et al. Severe tuberculosis induces unbalanced up-regulation of gene networks and overexpression of IL-22, MIP-1α, CCL27, IP-10, CCR4, CCR5, CXCR3, PD1, PDL2, IL-3, IFN-β, TIM1, and TLR2 but low antigen-specific cellular responses. J Infect Dis 2008; 198: 1514–1519.
Treerat P, Prince O, Cruz-Lagunas A, Muñoz-Torrico M, Salazar-Lezama MA, Selman M et al. Novel role for IL-22 in protection during chronic Mycobacterium tuberculosis HN878 infection. Mucosal Immunol 2017; 10: 1069–1081.
Zhang G, Chen X, Chan L, Zhang M, Zhu B, Wang L et al. An SNP selection strategy identified IL-22 associating with susceptibility to tuberculosis in Chinese. Sci Rep 2011; 1: 20.
Lutay N, Håkansson G, Alaridah N, Hallgren O, Westergren-Thorsson G, Godaly G. Mycobacteria bypass mucosal NF-kB signalling to induce an epithelial anti-inflammatory IL-22 and IL-10 response. PLoS One 2014; 9: e86466.
Yang C-S, Song C-H, Lee J-S, Jung S-B, Oh J-H, Park J et al. Intracellular network of phosphatidylinositol 3-kinase, mammalian target of the rapamycin/70 kDa ribosomal S6 kinase 1, and mitogen-activated protein kinases pathways for regulating mycobacteria-induced IL-23 expression in human macrophages. Cell Microbiol 2006; 8: 1158–1171.
Fazila N, Mat C, Zhang X, Guzzo C, Gee K. Interleukin-23-induced interleukin-23 receptor subunit expression is mediated by the Janus kinase/signal transducer and activation of transcription pathway in human CD4 T cells. J Interferon Cytokine Res 2011; 31: 363–371.
Gerosa F, Baldani-Guerra B, Lyakh LA, Batoni G, Esin S, Winkler-Pickett RT et al. Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med 2008; 205: 1447–1461.
Leepiyasakulchai C, Taher C, Chuquimia OD, Mazurek J, Söderberg-Naucler C, Fernández C et al. Infection rate and tissue localization of murine IL-12p40-producing monocyte-derived CD103(+) lung dendritic cells during pulmonary tuberculosis. PLoS One 2013; 8: e69287.
Gopal R, Lin Y, Obermajer N, Slight S, Nuthalapati N, Ahmed M et al. Interleukin-23 dependent IL-17 drives Th1 responses following Mycobacterium bovis BCG vaccination. Eur J Immunol 2012; 42: 364–373.
Huang Y, Matsumura Y, Hatano S, Noguchi N, Murakami T, Iwakura Y et al. IL-21 inhibits IL-17A-producing cd T-cell response after infection with Bacillus Calmette-Gue'rin via induction of apoptosis. Innate Immunity 2016; 22: 588–597.
Shen H, Gu J, Xiao H, Liang S, Yang E, Yang R et al. Selective destruction of interleukin 23-induced expansion of a major antigen-specific γδ T-cell subset in patients with tuberculosis. J Infect Dis 2017; 215: 420–430.
Cao Q, Li YY, He W-F, Zhang Z-Z, Zhou Q, Liu X et al. Interplay between microRNAs and the STAT3 signaling pathway in human cancers. Physiol Genomics 2013; 45: 1206–1214.
Ambros V. microRNAs: tiny regulators with great potential. Cell 2001; 107: 823–826.
Brent S, McKenzie RAKADJC. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006; 27: 17–23.
Shen L, Shen Y, Huang D, Qiu L, Sehgal P, Du GZ et al. Development of Vgamma2Vdelta2+ T cell responses during active mycobacterial coinfection of simian immunodeficiency virus-infected macaques requires control of viral infection and immune competence of CD4+ T cells. J Infect Dis 2004; 190: 1438–1447.
Zhong ZWZ, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science (New York, NY) 1994; 264: 95–98.
Huang G, Yan H, Ye S, Tong C, Ying Q-L. STAT3 phosphorylation at tyrosine 705 and serine 727 differentially regulates mouse ESC fates. Stem Cells 2014; 32: 1149–1160.
Elliott J, Suessmuth Y, Scott LM, Nahlik K, McMullin MF, Constantinescu SN et al. SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases. Haematologica 2009; 94: 576–580.
Liu Z, Gan L, Zhou Z, Jin W, Sun C. SOCS3 promotes inflammation and apoptosis via inhibiting JAK2/STAT3 signaling pathway in 3T3-L1 adipocyte. Immunobiology 2015; S0171-298500025-X.
Jung BG, Wang X, Yi N, Ma J, Turner J, Samten B. Early secreted antigenic target of 6-kDa of Mycobacterium tuberculosis stimulates IL-6 production by macrophages through activation of STAT3. Sci Rep 2017; 7: 40984.
Nagabhushanam V, Solache A, Ting L-M, Escaron CJ, Zhang JY, Ernst JD. Innate inhibition of adaptive immunity: Mycobacterium tuberculosis-induced IL-6 inhibits macrophage responses to IFN-gamma. J Immunol 2003; 171: 4750–4757.
Lienard J, Movert E, Valfridsson C, Sturegård E, Carlsson F. ESX-1 exploits type I IFN-signalling to promote a regulatory macrophage phenotype refractory to IFNγ-mediated autophagy and growth restriction of intracellular mycobacteria. Cell Microbiol 2016; 18: 1471–1485.
Siddiqui KF, Amir M, Gurram RK, Khan N, Arora A, Rajagopal K, Agrewala JN et al. Latency-associated protein Acr1 impairs dendritic cell maturation and functionality: a possible mechanism of immune evasion by Mycobacterium tuberculosis. J Infect Dis 2014; 209: 1436–1445.
Arcos J, Sasindran SJ, Moliva JI, Scordo JM, Sidiki S, Guo H et al. Mycobacterium tuberculosis cell wall released fragments by the action of the human lung mucosa modulate macrophages to control infection in an IL-10-dependent manner. Mucosal Immunol 2016; 10: 1248–1258.
Lastrucci C, Bénard A, Balboa L, Pingris K, Souriant S, Poincloux R et al. Tuberculosis is associated with expansion of a motile, permissive and immunomodulatory CD16(+) monocyte population via the IL-10/STAT3 axis. Cell Res 2015; 25: 1333–1351.
Martínez-Neri PA, López-Rincón G, Mancilla-Jiménez R, Toro-Arreola SD, Muñoz-Valle JF, Fafutis-Morris M et al. Prolactin modulates cytokine production induced by culture filtrate proteins of M. bovis through different signaling mechanisms in THP1 cells. Cytokine 2015; 71: 1.
Labzin LI, Lauterbach MAR, Latz E. Interferons and inflammasomes: cooperation and counterregulation in disease. J Allergy Clin Immunol 2016; 38: 37–46.
Polgar NCV, Szabo M, Zambo V, Melegh BI, Sumegi K, Nagy G, Tulassay Z, Melegh B. Investigation of JAK2, STAT3 and CCR6 polymorphisms and their gene-gene interactions in inflammatory bowel disease. Int J Immunogenet 2012; 39: 247–252.
Mishra BB, Lovewell RR, Olive AJ, Zhang G, Wang W, Eugenin E et al. Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis. Nat Microbiol 2017; 2: 17072.
Ye Z-J, Xu L-L, Zhou Q, Cui A, Wang X-J, Zhai K et al. Recruitment of IL-27-producing CD4(+) T cells and effect of IL-27 on pleural mesothelial cells in tuberculous pleurisy. Lung 2015; 193: 539–548.
Hölscher C, Hölscher A, Rückerl D, Yoshimoto T, Yoshida H, Mak T et al. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J Immunol 2005; 174: 3534–3544.
Kumar R, Sahu SK, Kumar M, Jana K, Gupta P, Gupta UD et al. MicroRNA 17-5p regulates autophagy in Mycobacterium tuberculosis-infected macrophages by targeting Mcl-1 and STAT3. Cell Microbiol 2016; 18: 679–691.
Yokoyama T, Kondo Y, Kondo S. Roles of mTOR and STAT3 in autophagy induced by telomere 3' overhang-specific DNA oligonucleotides. Autophagy 2007; 3: 496–498.
Deretic V, Delgado M, Vergne I, Master S, Haro SD, Ponpuak M et al. Autophagy in immunity against Mycobacterium tuberculosis: a model system to dissect immunological roles of autophagy. Curr Top Microbiol Immunol 2009; 335: 169–188.
Wei F, Zhong S, Ma Z, Kong H, Medvec A, Ahme R et al. Strength of PD-1 signaling differentially affects T-cell effector functions. Proc Natl Acad Sci USA 2013; 110: E2480–E2489.
Shen Y, Zhou D, Qiu L, Lai X, Simon M, Shen L et al. Adaptive immune response of Vγ2Vδ2+ T cells during mycobacterial infections. Science (New York, NY) 2002; 295: 2255–2258.
Bonnevillea M, Chen ZW, Déchanet-Mervillec J, Eberld M, Fourniée JJ, Jamesonf JM et al. Chicago 2014—30years of γδ T cells. Cell Immunol 2015; 296: 3–9.
de Jong R, Janson AA, Faber WR, Naafs B, Ottenhoff TH. IL-2 and IL-12 act in synergy to overcome antigen-specific T cell unresponsiveness in mycobacterial disease. J Immunol 1997; 159: 786–793.
Valle-Mendiola A, Weiss-Steider B, Rocha-Zavaleta L, Soto-Cruz I. IL-2 enhances cervical cancer cells proliferation and JAK3/STAT5 phosphorylation at low doses, while at high doses IL-2 has opposite effects. Cancer Invest 2014; 32: 115–125.
Chen CY, Huang D, Yao S, Halliday L, Zeng G, Wang RC et al. IL-2 simultaneously expands Foxp3+ T regulatory and T effector cells and confers resistance to severe tuberculosis (TB): implicative Treg-T effector cooperation in immunity to TB. J Immunol 2012; 199: 4278–4288.
Quan L, Chen X, Liu A, Zhang Y, Guo X, Yan S et al. PD-1 blockade can restore functions of T-Cells in Epstein–Barr virus-positive diffuse large B-cell lymphoma in vitro. PLoS One 2015; 10: e0136476.
Basile JI, Iatcovsky DK, Romero MM, Balboa L, Monteserin J, Ritacco V et al. Mycobacterium tuberculosis multi-drug-resistant strain M induces IL-17+ IFNγ− CD4+ T cell expansion through an IL-23 and TGF-β-dependent mechanism in patients with MDR-TB tuberculosis. Clin Exp Immunol 2017; 187: 160–173.
Radzikowska E, Roży A, Jaguś P, Wiatr E, Gawryluk D, Chorostowska-Wynimko J et al. Cryptogenic organizing pneumonia: IL-1β, IL-6, IL-8, and TGF- β1 serum concentrations and response to clarithromycin treatment. Adv Exp Med Biol 2016; 911: 77–85.
Chowdhury IH, Ahmed AM, Choudhuri S, Sen A, Hazra A, Pal NK et al. Alteration of serum inflammatory cytokines in active pulmonary tuberculosis following anti-tuberculosis drug therapy. Mol Immunol 2014; 62: 159–168.
Clifford V, Zufferey C, Street A, Denholm J, Tebruegge M, Curtis N. Cytokines for monitoring anti-tuberculous therapy: a systematic review. Tuberculosis 2015; 95: 217–218.
Stephen-Victor E, Sharma VK, Das M, Karnam A, Saha C, Lecerf M et al. IL-1β, but not programed death-1 and programed death ligand pathway, is critical for the human Th17 response to Mycobacterium tuberculosis. Front Immunol 2016; 7: 465.
Lyakh L, Trinchieri G, Provezza L, Carra G, Gerosa F. Regulation of interleukin-12/interleukin-23 production and the Thelper 17 response in humans. Immunol Rev 2008; 226: 112.
Kathamuthu GR, Moideen K, Baskaran D, Banurekha VV, Nair D, Sekar G et al. Tuberculous lymphadenitis is associated with enhanced baseline and antigen-specific induction of type 1 and type 17 cytokines and reduced interleukin-1β (IL-1β) and IL-18 at the site of infection. Clin Vaccine Immunol 2017; 24: e00045–00017.
Fremond CM, Togbe D, Doz E, Rose S, Vasseur V, Maillet I et al. IL-1 receptor-mediated signal is an essential component of MyD88-dependent innate response to Mycobacterium tuberculosis infection. J Immunol 2007; 179: 1178–1189.
Desel C, Werninghaus K, Ritter M, Jozefowski K, Wenzel J, Russkamp N et al. The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signaling. PLoS One 2013; 8: e53531.
Lyadova IV, Panteleev AV. Th1 and Th17 cells in tuberculosis: protection, pathology, and biomarkers. Mediat Inflamm 2015; 2015: 854507.
Liang SC, Long AJ, Bennett F, Whitters MJ, Karim R, Collins M et al. An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J Immunol 2007; 179: 7791–7799.
Lin PL, Maiello P, Gideon HP, Coleman MT, Cadena AM, Rodgers MA et al. PET CT identifies reactivation risk in cynomolgus macaques with latent M. tuberculosis. PLoS Pathog 2016; 12: e1005739.
Matthews K, Wilkinson KA, Kalsdorf B, Roberts T, Diacon A, Walzl G et al. Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosis. Tuberculosis (Edinb) 2011; 91: 587–593.
Qiu L, Huang D, Chen CY, Wang R, Shen L, Shen Y et al. Severe tuberculosis induces unbalanced up-regulation of gene networks and overexpression of IL-22, MIP-1alpha, CCL27, IP-10, CCR4, CCR5, CXCR3, PD1, PDL2, IL-3, IFN-beta, TIM1, and TLR2 but low antigen-specific cellular responses. J Infect Dis 2008; 198: 1514–1519.
Chen CY, Huang D, Yao S, Halliday L, Zeng G, Wang RC et al. IL-2 simultaneously expands Foxp3+ T regulatory and T effector cells and confers resistance to severe tuberculosis (TB): implicative Treg-T effector cooperation in immunity to TB. J Immunol 2012; 188: 4278–4288.
Bystrom J, Taher TE, Muhyaddin MS, Clanchy FI, Mangat P, Jawad AS et al. Harnessing the therapeutic potential of Th17 cells. Mediators Inflamm 2015; 2015: 205156.
Chen CY, Yao S, Huang D, Wei H, Sicard H, Zeng G et al. Phosphoantigen/IL2 expansion and differentiation of Vgamma2Vdelta2 T cells increase resistance to tuberculosis in nonhuman primates. PLoS Pathog 2013; 9: e1003501.
Bermudez LE, Stevens P, Kolonoski P, Wu M, Young LS. Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol 1989; 143: 2996–3000.